Adjusted Revenue

Adjusted Revenue %Chg

Adjusted Gross Profit

Adjusted Gross Profit %Chg

Adjusted Gross Margin

Adjusted Gross Margin %Chg

Adjusted EBIT

Adjusted EBIT %Chg

Adjusted EBIT Margin

Adjusted EBIT Margin %Chg

Adjusted EBITDA

Adjusted EBITDA %Chg

Adjusted EBITDA Margin

Adjusted EBITDA Margin %Chg

Adjusted Net Income

Adjusted Net Income %Chg

Adjusted Net Income Margin

Adjusted Net Income Margin %Chg

Adjusted EPS

Adjusted EPS %Chg

Adjusted Free Cash Flow (FCF)

Adjusted Free Cash Flow (FCF) %Chg

Adjusted Free Cash Flow Margin

Adjusted Free Cash Flow Margin %Chg

Adjusted Capital Expenditures

Adjusted Capital Expenditures %Chg

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Metric	Dec '26 (E)	Sep '26 (E)	Jun '26 (E)	Mar '26 (E)	Dec '25 (E)	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23	Mar '23	Dec '22	Sep '22	Jun '22	Mar '22	Dec '21	Sep '21	Jun '21	Mar '21	Dec '20
Adjusted Revenue					156.1
Adjusted Gross Profit					—
Adjusted Gross Margin					—
Adjusted EBIT					15
Adjusted EBIT Margin					9.6%
Adjusted EBITDA					26.7
Adjusted EBITDA Margin					17.1%
Adjusted Net Income					13.6
Adjusted Net Income Margin					8.7%
Adjusted EPS					0.4
Adjusted Free Cash Flow (FCF)					19
Adjusted Free Cash Flow Margin					12.2%
Adjusted Capital Expenditures					-15